Astellas Pharma Inc., commonly referred to as Astellas, is a leading global pharmaceutical company headquartered in Tokyo, Japan. Founded in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in innovative medicines, Astellas focuses on areas such as oncology, urology, immunology, and neuroscience. The company is renowned for its commitment to research and development, which has led to the introduction of unique therapies that address unmet medical needs. Astellas has achieved notable market recognition, consistently ranking among the top pharmaceutical firms worldwide, thanks to its dedication to improving patient outcomes and advancing healthcare solutions.
How does Astellas's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Astellas's score of 44 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Astellas Pharma Inc., headquartered in Japan, reported total greenhouse gas emissions of approximately 1,222,500,000 kg CO2e globally. This figure includes 59,203,000 kg CO2e from Scope 1 emissions and 63,047,000 kg CO2e from Scope 2 emissions. Notably, Scope 3 emissions accounted for a significant 1,121,350,000 kg CO2e, highlighting the importance of addressing indirect emissions in their climate strategy. Astellas has set ambitious targets to reduce its carbon footprint. The company aims for a 63% reduction in Scope 1 and 2 emissions by fiscal year 2030, using 2015 as the baseline year. Additionally, Astellas is committed to reducing its Scope 3 emissions by 37.5% by the same year. These targets align with the Science Based Targets initiative (SBTi) and are designed to keep global warming below 1.5°C. Furthermore, Astellas has pledged to achieve net-zero greenhouse gas emissions across all scopes by 2050, reinforcing its commitment to sustainable practices and climate responsibility. This long-term goal reflects the company's proactive approach to mitigating climate change impacts and enhancing its environmental stewardship.
Access structured emissions data, company-specific emission factors, and source documents
| 2005 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 108,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Astellas is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
